Tela Bio Inc (TELA)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $34.42M
Last updated: Nov 17, 2026 at 4:10 PM ET
Tela Bio Inc (TELA) Statistics
Tela Bio (TELA) has a market cap of $34.42M and an enterprise value of $68.05M. Its share count is up 27.01% from a year earlier. It kept -53.57% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 97.73% above the market cap, as debt exceeds cash.
| Market Cap | $34.42M |
|---|---|
| Enterprise Value | $68.05M |
| Latest price (Nov 17, 2026) | $0.76 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 0.6x. Its year-end P/S ranged from 0.7x to 10.8x from 2019 to 2025.
| P/S Ratio | 0.6x |
|---|---|
| Forward P/S | 0.4x |
Price Statistics
The stock is down 23.74% over 52 weeks and trades 26.21% below its 50-day average.
| Beta (1Y) | 1.43 |
|---|---|
| 52-Week Change | -23.74% |
| 1-Month Change | -21.46% |
| 3-Month Change | +17.79% |
| 6-Month Change | -11.38% |
| 5-Year Change | -93.71% |
| Total Return (1Y) | -23.74% |
| Total Return (3Y CAGR) | -45.42% |
| Total Return (5Y CAGR) | -43.00% |
| Max Drawdown (1Y) | -52.52% |
| Max Drawdown (3Y) | -92.64% |
| Sharpe Ratio (1Y) | -0.47 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $1.03 |
| 200-Day Average | $0.85 |
| 52-Week Range | $0.50 to $1.50 |
| RSI (14 Days) | 39.2 |
| Average Volume (20 Days) | 140.84K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.61x current liabilities.
| Current Ratio | 0.61x |
|---|---|
| Quick Ratio | 0.45x |
| Interest Coverage | -3.74x |
Returns and Efficiency
Return on invested capital is -103.26% over the last 12 months, against a 5-year average of -52.40%.
| Return on Assets (ROA) | -84.61% |
|---|---|
| Return on Invested Capital (ROIC) | -103.26% |
| ROA (5Y Average) | -53.94% |
| ROIC (5Y Average) | -52.40% |
| Asset Turnover | 1.41x |
| Inventory Turnover | 2.20x |
| Receivables Turnover | 8.27x |
| Cash Conversion Cycle | 171 days |
Scores
TELA has an Altman Z-Score of -13.11, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -13.11 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $78.18M over the last 12 months is up 1.46% from the 12 months before.
| Revenue | $78.18M |
|---|---|
| Revenue Growth (YoY) | +1.46% |
| Gross Profit | $52.53M |
| Operating Income | -$33.75M |
| Pretax Income | -$41.51M |
| Net Income | -$41.88M |
| EBITDA | -$31.73M |
| EBIT | -$32.76M |
| Reported EPS (TTM) | -$0.71 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $22.66M |
|---|---|
| Total Debt | $56.30M |
| Net Debt | $33.63M |
| Net Debt Per Share | $0.58 |
| Working Capital | -$28.26M |
| Shareholder Equity | -$24.58M |
| Tangible Book Value | -$25.65M |
| Total Assets | $49.49M |
| Total Liabilities | $74.07M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $276.00K of capital spending, operating cash flow left -$34.39M of free cash flow.
| Operating Cash Flow | -$34.11M |
|---|---|
| Capital Expenditures | $276.00K |
| Free Cash Flow | -$34.39M |
| FCF Per Share | -$0.76 |
| Depreciation and Amortization | $1.02M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -43.17%, against a 5-year average of -72.16%.
| Gross Margin | 67.19% |
|---|---|
| Operating Margin | -43.17% |
| Pretax Margin | -53.10% |
| Net Margin | -53.57% |
| EBITDA Margin | -40.59% |
| EBIT Margin | -41.90% |
| FCF Margin | -43.99% |
| Gross Margin (5Y Average) | 66.51% |
| Operating Margin (5Y Average) | -72.16% |
| Net Margin (5Y Average) | -80.54% |
Growth
Revenue grew 24.68% a year over 3 years.
| Revenue Growth (3Y CAGR) | +24.68% |
|---|---|
| Revenue Growth (5Y CAGR) | +34.54% |
| Book Value Per Share Growth (2Y CAGR) | -60.20% |
| Tangible Book Per Share Growth (2Y CAGR) | -62.58% |
Dividends and Yields
TELA does not pay a dividend. Its free cash flow yield is -78.22%.
| FCF Yield | -78.22% |
|---|---|
| Buyback Yield | 0.45% |
| Shareholder Yield | 0.45% |
Peer Position
Against 11 similar companies, TELA has the 10th highest P/S.
P/S RatioPeer median 1.3x
ROICPeer median -111.14%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.15%
| P/S Ratio | 0.6x vs 1.3x median |
|---|---|
| ROIC | -103.26% vs -111.14% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1.46% vs +9.15% median |
Analyst Forecast
Consensus estimates put revenue growth at 1.84% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1.84% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TELA
What is TELA's market cap?
Tela Bio has a market cap of $34.42M. Its enterprise value, which adds debt and subtracts cash, is $68.05M.
How many shares of TELA are outstanding?
Tela Bio has 57.69M shares outstanding. The count is up 27.01% from a year earlier.
Does TELA pay a dividend?
No. Tela Bio does not pay a dividend.
How much debt does TELA have?
Tela Bio has $56.30M of total debt and $22.66M of cash and equivalents, a net debt position of $33.63M.
TELA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts